These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 28215406)

  • 1. Direct oral anticoagulants for superficial-vein thrombosis.
    Ageno W; Dentali F
    Lancet Haematol; 2017 Mar; 4(3):e95-e96. PubMed ID: 28215406
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of direct oral anticoagulants in patients with cerebral venous thrombosis.
    Li A; Zhu W; Liu X
    Eur J Intern Med; 2024 Aug; 126():123-124. PubMed ID: 38631973
    [No Abstract]   [Full Text] [Related]  

  • 3. Direct oral anticoagulants in rare venous thrombosis.
    Finazzi G; Ageno W
    Intern Emerg Med; 2016 Mar; 11(2):167-70. PubMed ID: 26875179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban for the treatment of superficial vein thrombosis, experience at King's College Hospital.
    Clapham RE; Speed V; Czuprynska J; Gazes A; Guppy S; Patel RK; Rea C; Vadher B; Arya R; Roberts LN
    Br J Haematol; 2022 Jan; 196(1):e3-e6. PubMed ID: 34355385
    [No Abstract]   [Full Text] [Related]  

  • 5. Home treatment of deep venous thrombosis in the era of new oral anticoagulants.
    Stein PD; Matta F; Hughes PG; Ghiardi M; Marsh JH; Khwarg J; Brandon MS; Fowkes HA; Kazan V; Wiepking M; Keyes DC; Kakish EJ; Hughes MJ
    Clin Appl Thromb Hemost; 2015 Nov; 21(8):729-32. PubMed ID: 26239315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poor response to rivaroxaban in nephrotic syndrome with acute deep vein thrombosis: A case report.
    Li Y; Chen Y; Qi X; Hu B; Du Q; Qian Y
    Medicine (Baltimore); 2019 Aug; 98(31):e16585. PubMed ID: 31374026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful use of rivaroxaban in postoperative deep vein thrombosis of the lower limb following instability with warfarin: a case report.
    Schiavoni M; Coluccia A
    J Med Case Rep; 2016 Oct; 10(1):276. PubMed ID: 27716428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A first described case of cancer-associated non-bacterial thrombotic endocarditis in the era of direct oral anticoagulants.
    Mantovani F; Navazio A; Barbieri A; Boriani G
    Thromb Res; 2017 Jan; 149():45-47. PubMed ID: 27888769
    [No Abstract]   [Full Text] [Related]  

  • 9. Addendum to British Society for Haematology guideline on the investigation, management and prevention of venous thrombosis in children (Br. J. Haematol. 2011; 154: 196-207).
    Biss TT; Chalmers EA
    Br J Haematol; 2021 Sep; 194(6):996-998. PubMed ID: 34462907
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of rivaroxaban mono-therapy and standard-therapy adjusted by CYP2C9 and VKORC1 genotypes in symptomatic pulmonary embolism.
    Duan L; Zhang N; Yan H; Guo Y; Hong C; Yang X; Su X; Chen R; Zhou Y; Zhong N; Liu C
    Clin Chim Acta; 2016 Aug; 459():25-29. PubMed ID: 27155586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome.
    Malec K; Góralczyk T; Undas A
    Thromb Res; 2017 Apr; 152():93-97. PubMed ID: 27989533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban as anticoagulant therapy in short bowel syndrome. Report of three cases.
    Christensen LD; Vinter-Jensen L; Rasmussen HH; Kristensen SR; Larsen TB
    Thromb Res; 2015 Mar; 135(3):568-70. PubMed ID: 25592650
    [No Abstract]   [Full Text] [Related]  

  • 13. Tonsillectomy on rivaroxaban.
    Saini AT; Schorn VJ; Lin FY
    Am J Otolaryngol; 2015; 36(2):280-2. PubMed ID: 25456169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of New Oral Anticoagulants (NOACs) in Cancer Patients.
    Ravikumar R; Lim CS; Davies AH
    Adv Exp Med Biol; 2017; 906():137-148. PubMed ID: 27620312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions.
    Margolis JM; Deitelzweig S; Kline J; Tran O; Smith DM; Bookhart B; Crivera C; Schein J
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
    Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
    Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability of direct oral anticoagulants in whole blood and plasma from patients in steady state treatment.
    McGrail R; Revsholm J; Nissen PH; Grove EL; Hvas AM
    Thromb Res; 2016 Dec; 148():107-110. PubMed ID: 27835819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Not Available].
    Steurer J
    Praxis (Bern 1994); 2018 Jan; 107(3):167-168. PubMed ID: 29382267
    [No Abstract]   [Full Text] [Related]  

  • 19. Healthcare burden associated with the post-thrombotic syndrome and potential impact of the new oral anticoagulants.
    Prandoni P
    Eur J Haematol; 2012 Mar; 88(3):185-94. PubMed ID: 22077374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivaroxaban for the treatment and prevention of thromboembolic disease.
    Antoniou S
    J Pharm Pharmacol; 2015 Aug; 67(8):1119-32. PubMed ID: 26059702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.